Can diabetes drugs stop heart disease? new trial aims to find out

NCT ID NCT07254572

Recruiting now Disease control Sponsor: National Institute of Cardiology, Warsaw, Poland Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 21 times

Summary

This study compares two diabetes drugs, semaglutide and dapagliflozin, against the standard treatment metformin in 300 adults with pre-diabetes and coronary artery disease. The goal is to see if these drugs can slow or reverse the buildup of fatty plaque in the heart arteries over 24 months. Participants will have CT scans to measure changes in their arteries.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institute of Cardiology, Department of Coronary Artery and Structural Heart Diseases
RECRUITING

Warsaw, Poland

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

CORONARY ARTERY DISEASE PREDIABETES PREDIABETES